REGENXBIO (RGNX) Stock Overview
A clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
RGNX Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
REGENXBIO Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.49 |
| 52 Week High | US$15.36 |
| 52 Week Low | US$5.04 |
| Beta | 1.06 |
| 1 Month Change | 0.71% |
| 3 Month Change | 8.57% |
| 1 Year Change | -33.52% |
| 3 Year Change | -72.79% |
| 5 Year Change | -77.17% |
| Change since IPO | -72.12% |
Recent News & Updates
Recent updates
REGENXBIO Inc. Just Missed EPS By 64%: Here's What Analysts Think Will Happen Next
May 15
REGENXBIO Inc. (NASDAQ:RGNX) Shares Fly 34% But Investors Aren't Buying For Growth
May 01Is REGENXBIO (NASDAQ:RGNX) A Risky Investment?
Apr 24
FDA Approval And Nippon Shinyaku Partnership Will Advance Pipeline
Strategic partnerships and FDA approvals drive potential revenue growth through new market penetrations and milestone payments.5 Reasons To Buy Regenxbio Right Now
Mar 26The Market Doesn't Like What It Sees From REGENXBIO Inc.'s (NASDAQ:RGNX) Revenues Yet As Shares Tumble 27%
Mar 04Regenxbio Inc.: Why It Is Down, And When It Will Go Up Again
Jan 15Revenues Working Against REGENXBIO Inc.'s (NASDAQ:RGNX) Share Price Following 26% Dive
Dec 28REGENXBIO: With Additional MPS II Data, Program Advancement Remains On Track
Oct 31Does REGENXBIO (NASDAQ:RGNX) Have A Healthy Balance Sheet?
Sep 12Regenxbio: RGX-121 Could Achieve A First For Rare Neurodegenerative Disorder
Aug 06REGENXBIO Inc. (NASDAQ:RGNX) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Aug 04Revenues Working Against REGENXBIO Inc.'s (NASDAQ:RGNX) Share Price
Jul 26Regenxbio: Transforming Gene Therapy With Innovative AAV Treatments, Strong Buy
Jun 11REGENXBIO Inc. (NASDAQ:RGNX) Analysts Are Cutting Their Estimates: Here's What You Need To Know
May 11REGENXBIO Inc. (NASDAQ:RGNX) Not Doing Enough For Some Investors As Its Shares Slump 26%
Apr 25Regenxbio: DMD Program Lends Additional Credibility To NAV Technology Platform
Mar 11Analysts Just Slashed Their REGENXBIO Inc. (NASDAQ:RGNX) EPS Numbers
Mar 07Improved Revenues Required Before REGENXBIO Inc. (NASDAQ:RGNX) Stock's 75% Jump Looks Justified
Mar 05Earnings Update: REGENXBIO Inc. (NASDAQ:RGNX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Mar 02Regenxbio: Robust Data, Decent Cash, Never Ending Trials, Buying At Dips
Jan 19Shareholder Returns
| RGNX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.4% | -1.7% | 0.8% |
| 1Y | -33.5% | -13.2% | 13.7% |
Return vs Industry: RGNX underperformed the US Biotechs industry which returned -11.9% over the past year.
Return vs Market: RGNX underperformed the US Market which returned 14.8% over the past year.
Price Volatility
| RGNX volatility | |
|---|---|
| RGNX Average Weekly Movement | 14.6% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: RGNX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: RGNX's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 353 | Curran Simpson | www.regenxbio.com |
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase III clinical trial for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II.
REGENXBIO Inc. Fundamentals Summary
| RGNX fundamental statistics | |
|---|---|
| Market cap | US$411.17m |
| Earnings (TTM) | -US$157.69m |
| Revenue (TTM) | US$156.72m |
Is RGNX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RGNX income statement (TTM) | |
|---|---|
| Revenue | US$156.72m |
| Cost of Revenue | US$30.96m |
| Gross Profit | US$125.76m |
| Other Expenses | US$283.44m |
| Earnings | -US$157.69m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.13 |
| Gross Margin | 80.24% |
| Net Profit Margin | -100.62% |
| Debt/Equity Ratio | 19.6% |
How did RGNX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/21 14:22 |
| End of Day Share Price | 2025/07/21 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
REGENXBIO Inc. is covered by 23 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Huidong Wang | Barclays |
| Alec Stranahan | BofA Global Research |